These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37927432)

  • 1. Universal infant immunisation against respiratory syncytial virus and European inequalities: the pandemics lesson has not been learnt.
    De Luca D; Sanchez-Luna M; Schettler K; Bont L; Baraldi E
    Lancet Reg Health Eur; 2023 Nov; 34():100753. PubMed ID: 37927432
    [No Abstract]   [Full Text] [Related]  

  • 2. Group B streptococcus and respiratory syncytial virus immunisation during pregnancy: a landscape analysis.
    Heath PT; Culley FJ; Jones CE; Kampmann B; Le Doare K; Nunes MC; Sadarangani M; Chaudhry Z; Baker CJ; Openshaw PJM
    Lancet Infect Dis; 2017 Jul; 17(7):e223-e234. PubMed ID: 28433702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of strategies for preventing paediatric lower respiratory infections associated with respiratory syncytial virus in eight Chinese cities.
    Liu D; Leung K; Jit M; Wu JT
    Vaccine; 2021 Sep; 39(39):5490-5498. PubMed ID: 34454783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the Effects of Active Immunisation against Respiratory Syncytial Virus (RSV) using Decision-Analytic Models: A Systematic Review with a Focus on Vaccination Strategies, Modelling Methods and Input Data.
    Treskova M; Pozo-Martin F; Scholz S; Schönfeld V; Wichmann O; Harder T
    Pharmacoeconomics; 2021 Mar; 39(3):287-315. PubMed ID: 33462760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Passive immunisation against respiratory syncytial virus: a cost-effectiveness analysis.
    Rietveld E; Steyerberg EW; Polder JJ; Veeze HJ; Vergouwe Y; Huysman MW; de Groot R; Moll HA
    Arch Dis Child; 2010 Jul; 95(7):493-8. PubMed ID: 20504841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Waning Immunity Against Respiratory Syncytial Virus During the Coronavirus Disease 2019 Pandemic.
    Reicherz F; Xu RY; Abu-Raya B; Majdoubi A; Michalski C; Golding L; Stojic A; Vineta M; Granoski M; Cieslak Z; Chacko A; Desai N; Sekirov I; Marchant DJ; Lavoie PM
    J Infect Dis; 2022 Dec; 226(12):2064-2068. PubMed ID: 35524952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The increasing age of respiratory syncytial virus-related hospitalisation during COVID-19 pandemic in Lyon was associated with reduced hospitalisation costs.
    Roy Á; Polazzi S; Ploin D; Gillet Y; Javouhey E; Lina B; ; Myard-Dury AF; Couray-Targe S; Duclos A; Casalegno JS
    Vaccine; 2023 Jun; 41(25):3796-3800. PubMed ID: 37198017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Pandemic on the Epidemiology of Pediatric Respiratory Syncytial Virus Infection.
    Odumade OA; van Haren SD; Angelidou A
    Clin Infect Dis; 2022 Aug; 75(Suppl 1):S130-S135. PubMed ID: 35579506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Respiratory syncytial virus seasonality and prevention strategy planning for passive immunisation of infants in low-income and middle-income countries: a modelling study.
    Li Y; Hodgson D; Wang X; Atkins KE; Feikin DR; Nair H
    Lancet Infect Dis; 2021 Sep; 21(9):1303-1312. PubMed ID: 33965062
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cost-benefit analysis of the immunisation of children against respiratory syncytial virus (RSV) using the English Hospital Episode Statistics (HES) data set.
    Thomas G
    Eur J Health Econ; 2018 Mar; 19(2):177-187. PubMed ID: 25557555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunisation: leaps into the future. The flu virus and syncytial respiratory virus: strategies for active immunisation].
    Mato Chaín G; Mariano Lázaro A; Rodríguez Caravaca G; Fereres Castiel J
    Aten Primaria; 2002 Sep; 30(4):243-7. PubMed ID: 12237030
    [No Abstract]   [Full Text] [Related]  

  • 12. Early and intense epidemic of respiratory syncytial virus (RSV) in Denmark, August to December 2022.
    Munkstrup C; Lomholt FK; Emborg HD; Møller KL; Krog JS; Trebbien R; Vestergaard LS
    Euro Surveill; 2023 Jan; 28(1):. PubMed ID: 36695451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study.
    Wildenbeest JG; Billard MN; Zuurbier RP; Korsten K; Langedijk AC; van de Ven PM; Snape MD; Drysdale SB; Pollard AJ; Robinson H; Heikkinen T; Cunningham S; O'Neill T; Rizkalla B; Dacosta-Urbieta A; Martinón-Torres F; van Houten MA; Bont LJ;
    Lancet Respir Med; 2023 Apr; 11(4):341-353. PubMed ID: 36372082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seasonality of respiratory syncytial virus and its association with meteorological factors in 13 European countries, week 40 2010 to week 39 2019.
    Li Y; Wang X; Broberg EK; Campbell H; Nair H;
    Euro Surveill; 2022 Apr; 27(16):. PubMed ID: 35451364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unraveling the effects of the COVID-19 pandemic on the hospital burden of respiratory syncytial virus.
    Perramon-Malavez A; López de Rioja V; Creus-Costa A; Andrés C; Montañola-Sales C; Vila J; Lera E; Antón A; Worner N; Balcells J; Piñana M; Soler-Palacin P; Prats C; Soriano-Arandes A
    Pediatr Pulmonol; 2023 Oct; 58(10):2979-2982. PubMed ID: 37493108
    [No Abstract]   [Full Text] [Related]  

  • 16. Lessons to learn from the current pandemic for future non-pharmaceutical interventions against the respiratory syncytial virus - nationwide register-study in Finland.
    Kuitunen I; Renko M
    Infect Dis (Lond); 2021 Jun; 53(6):476-478. PubMed ID: 33685331
    [No Abstract]   [Full Text] [Related]  

  • 17. Recommendations for respiratory syncytial virus surveillance at the national level.
    Teirlinck AC; Broberg EK; Stuwitz Berg A; Campbell H; Reeves RM; Carnahan A; Lina B; Pakarna G; Bøås H; Nohynek H; Emborg HD; Nair H; Reiche J; Oliva JA; O'Gorman J; Paget J; Szymanski K; Danis K; Socan M; Gijon M; Rapp M; Havlíčková M; Trebbien R; Guiomar R; Hirve SS; Buda S; van der Werf S; Meijer A; Fischer TK
    Eur Respir J; 2021 Sep; 58(3):. PubMed ID: 33888523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Respiratory syncytial virus prophylaxis in children with cardiac disease: a retrospective single-centre study.
    Butt M; Symington A; Janes M; Steele S; Elliott L; Chant-Gambacort C; Mondal T; Paes B
    Cardiol Young; 2014 Apr; 24(2):337-43. PubMed ID: 23628233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The European Forum for Clinical Management: prophylaxis against the respiratory syncytial virus in infants and young children with congenital cardiac disease.
    Tulloh RM; Feltes TF
    Cardiol Young; 2005 Jun; 15(3):274-8. PubMed ID: 15865829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Respiratory Syncytial Virus Infections in Young Children Presenting to Primary Care in Catalonia During the COVID-19 Pandemic.
    Coma E; Vila J; Méndez-Boo L; Antón A; Mora N; Fina F; Fàbregas M; Medina M
    J Pediatric Infect Dis Soc; 2022 Feb; 11(2):69-72. PubMed ID: 34922377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.